biomedicines

IMPACT FACTOR 4.7

Indexed in: PubMed

CITESCORE 3.7

an Open Access Journal by MDPI

Hereditary Gastrointestinal Cancer Syndromes: Molecular Basis of Onset and Progression, Molecular Diagnosis, and Precision Therapy

Collection Editor:

Prof. Dr. Marina De Rosa

1. Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy
2. Ceinge Biotecnologie Avanzate, 80131 Naples, Italy

Message from the Collection Editor

This Topical Collection, entitle “Hereditary Gastrointestinal Cancer Syndromes: Molecular Basis of Onset and Progression, Molecular Diagnosis, and Precision Therapy” will mainly focus on the principal roles that hereditary gastrointestinal cancer predisposing syndromes plays on colorectal cancer incidence, the molecular basis of their onset and progression, the discovery of innovative therapies for disease management and care, and the standardization of novel approaches for early diagnosis and cancer prevention.<false,>Colorectal cancer (CRC) is the third most frequent cancer worldwide. About 75% of all CRCs are sporadic cancers and arise following somatic mutations, while about 10% of all CRCs are hereditary cancers, among which are hereditary nonpolyposis colorectal cancer, adenomatous and hamartomatous polyposis syndromes, and gastric adenocarcinoma and proximal polyposis of the stomach. <false,>We thus consider this subject to be of particular interest because new knowledge can help toward early asymptomatic diagnosis, cancer prevention, and standardization of new therapeutic approaches.

mdpi.com/si/111747

Topical Collection

biomedicines

IMPACT FACTOR 4.7 | Indexed in: PubMed | CITESCORE 3.7

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI